

32. The kit of claim 29, wherein the nucleic acid is an expression vector.
33. The kit of claim 29, wherein a viral particle contains the nucleic acid.
34. The kit of claim 29, further comprising a liposome.
35. The kit of claim 29, wherein the nucleic acid further encodes a second gene.
36. The kit of claim 35, wherein the second gene encodes a cytotoxic agent.
37. The kit of claim 36, wherein the cytotoxic agent is selected from the group consisting of thymidine kinase, cytosine deaminase, and nitric oxide synthetase.
38. The kit of claim 37, wherein the cytotoxic agent is thymidine kinase.
39. The kit of claim 35, wherein the gene encoding p27 and the second gene are operatively linked.
40. The kit of claim 39, wherein the gene encoding p27 and the second gene are operatively linked such that they form a fusion protein.
41. The kit of claim 40, wherein the fusion protein is a p27-thymidine kinase fusion protein.
-

REMARKS

Many of the above amendments to the specification were made to conform the specification with the Sequence Listing submitted in the previous application. The amendments to "FACscan" and "CELLquest" are made to properly refer to trademarks in the specification. The Examiner should note that at page 7, line 7; page 15, line 19; and page 19, line 21, the specification is being amended to correct a typographical error. The specification as filed incorrectly refers to an amino acid sequence as "GGAA." The correct amino acid sequence is "AAGG." Support for the correct sequence can be found in FIG. 4A. Further support that this is the correct sequence can be found by translating the oligonucleotides used to create the corresponding amino acid sequence. Oligonucleotide #24 (page 15, line 23) contains the nucleic acid sequence GCG GCC GGG GGG. When translated, this nucleic acid sequence encodes the amino acid sequence alanine-alanine-glycine-glycine (AAGG).

Applicants hereby submit that the above amendments do not represent new matter. Amendments were made to correct errors in the specification or to have the specification correctly correspond to the Sequence Listing.

Support for the newly added claims can be found throughout the specification and in the original claims. In particular, support for the claims can be found at least at pages 7-14; Example 1, pages 14-16; Example 2, pages 20-23; and within U.S. Patent No. 5,328,470, which is incorporated by reference at page 12, line 17 along with page 31, lines 5-6.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read 'T. Wrona', is written over a horizontal line.

Thomas J. Wrona, Ph.D.
Registration No. 44,410

BRINKS HOFER GILSON & LIONE
P.O. BOX 10395
CHICAGO, ILLINOIS 60610
(312) 321-4200